Table 2 Subgroup analysis of Atezolizumab versus chemotherapy for urothelial carcinoma
Subgroup | OS | |||
|---|---|---|---|---|
Study | HR [95%CI] | P value | I2 | |
Total | 10 | 0.88 [0.83–0.94] | < 0.0001 | 0% |
Region | ||||
Asia | 1 | 1.13 [0.84–1.52] | 0.42 | NA |
Europe | 6 | 0.86 [0.80–0.93] | < 0.0001 | 0% |
America | 3 | 0.90 [0.79–1.02] | 0.1 | 15% |
Intervention | ||||
Atezolizumab monotherapy | 7 | 0.90 [0.83–0.98] | 0.02 | 14% |
Atezolizumab plus Chemotherapy | 3 | 0.84 [0.75–0.94] | 0.002 | 0% |